Hologic, Inc. Faces Market Challenges Amid Financial Adjustments

Marlborough, Massachusetts-based Hologic, Inc. (HOLX) focuses on developing, manufacturing, and supplying diagnostics products, medical imaging systems, and surgical products for women’s health. The company holds a market capitalization of $12.3 billion and is recognized for its expertise in breast health, diagnostics, and gynecologic surgical solutions.

Performance Against the Market

Over the past year, Hologic has struggled significantly compared to the broader market. Shares of HOLX have fallen by 26.8%, while the S&P 500 Index ($SPX) has gained 12.3%. Year-to-date, HOLX is down 23.2%, contrasting with a slight increase in the SPX.

Comparative Sector Analysis

Focusing on sector performance, HOLX has underperformed relative to the SPDR S&P Health Care Equipment ETF’s (XHE), which has seen a 5.1% decline over the past 52 weeks and a 7.6% drop year-to-date.

Q2 Financial Results

On May 1, Hologic reported its Q2 results, revealing adjusted earnings of $1.03 per share and a revenue of $1 billion, both slightly exceeding expectations. Despite this, the stock dropped 5.5% in the following trading session. This decline was primarily due to a lowered fiscal 2025 adjusted EPS guidance, which reflects the impacts of tariffs and geopolitical uncertainties. Hologic now anticipates an adjusted EPS in the range of $4.15 to $4.25, alongside estimated revenue between $4.05 billion and $4.1 billion. Additionally, Q2 revenue dropped 1.2% year-over-year, mainly due to reduced sales in mammography capital equipment.

Forecast and Analyst Ratings

For the current fiscal year ending in September, analysts project Hologic’s EPS to rise by 3.2% year-over-year to $4.21. The company’s earnings surprise history shows mixed results, exceeding consensus estimates in three of the last four quarters while missing once.

Among the 19 analysts covering HOLX, the consensus rating stands at “Moderate Buy,” which includes five “Strong Buy,” one “Moderate Buy,” and 13 “Hold” ratings. This sentiment has softened slightly from three months ago when six analysts had recommended a “Strong Buy” rating.

Price Targets

On May 13, Stephens maintained an “Overweight” rating on HOLX but lowered its price target to $70, indicating a potential upside of 26.4% from current levels. Furthermore, the mean price target of $70.20 suggests a 26.8% premium over Hologic’s current prices, while the highest target at $95 indicates a substantial upside of 71.6%.

On the date of publication, Neharika Jain did not hold any positions in the securities mentioned. All information and data presented herein is for informational purposes only. For more details, refer to the Barchart Disclosure Policy here.

The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.